SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination.
SARS-CoV-2 Delta variant breakthrough infections in nursing home residents following vaccination with Comirnaty® COVID-19 vaccine were characterized. In total, 201 participants (median age, 87 years; range, 64-100; 133 female) from two nursing homes in the Valencian community (Spain) were included....
| Autores: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL) |
| Repositorio: | r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante |
| OAI Identifier: | oai:isabial.fundanetsuite.com:p8697 |
| Acceso en línea: | https://isabial.portalinvestigacion.com/publicaciones8697 |
| Access Level: | acceso abierto |
| Palabra clave: | Comirnaty® COVID-19 vaccine SARS-CoV-2 Delta variant Spike-reactive T cells. anti-Spike antibodies breakthrough infection nursing home residents |
| Sumario: | SARS-CoV-2 Delta variant breakthrough infections in nursing home residents following vaccination with Comirnaty® COVID-19 vaccine were characterized. In total, 201 participants (median age, 87 years; range, 64-100; 133 female) from two nursing homes in the Valencian community (Spain) were included. SARS-CoV-2-Spike (S) antibody responses were determined by a lateral flow immunocromatography (LFIC) assay and by quantitative electrochemiluminescent assay in LFIC-negative participants. SARS-CoV-2-S-IFN? T cells were enumerated by flow cytometry in 10 participants. Nasopharyngeal SARS-CoV-2 RNA loads were quantified by RT-PCR assays. Vaccine breakthrough COVID-19 due to the Delta variant occurred in 39 residents (median age, 87 years; range, 69-96; 31 female) at a median of 6.5 months after vaccination (9 requiring hospitalization). Breakthrough infections occurred at a higher rate (P<0.0001) in residents who had not been previously infected with SARS-CoV-2 (naïve) (33/108; 18%) than in those with prior diagnosis of SARS-CoV-2 infection (experienced) (6/93; 6.4%), and were more likely (P<0.0001) to develop in residents who tested negative by LFIC (20/49) at 3 months (3M) after vaccination as compared to their LFIC-positive counterparts (19/142). Among LFIC-negative residents, a trend towards lower plasma anti-RBD antibody levels were noticed in those developing breakthrough infection (P=0.16). SARS-CoV-2 RNA loads in nasopharyngeal specimens were lower in SARS-CoV-2-experienced residents (P<0.001) and in those testing positive by LFIC (P=0.13). Frequency of SARS-CoV-2-S-reactive T cells at 3 months was similar in LFIC-negative residents with (n=7) or without (n=3) breakthrough infection. Prior history of SARS-CoV-2 infection and detection of S-reactive antibodies by LFIC at 3 months are associated with a lower risk of Delta-variant breakthrough infection in nursing home residents at mid-term after Comirnaty® COVID-19 vaccination. This article is protected by copyright. All rights reserved. |
|---|